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Abstract
The anti-cancer drug cisplatin (cis-diamminedichloroplatinum(II)) forms a stable coordination complex with
phosphatidylserine (PS) in model membrane systems (Speelmans et al., Biochemistry 36 (1997) 10545^10550). Because a
similar interaction in vivo would be expected to have important physiological implications we studied cisplatin-PS interaction
in human erythrocytes and tumor cell lines. Although cisplatin was efficiently taken up by intact erythrocytes, a cisplatin-PS
complex was only detected in cells which had lysed as a result of prolonged storage or hypotonic shock. Despite the use of
highly sensitive detection methods, and despite efficient cellular uptake of cisplatin, a complex could also not be detected in
four human tumor cell lines, unless cells were permeabilized. In experiments in which cisplatin was incubated with
PS-containing liposomes in the presence of an alternative cellular substrate, such as reduced glutathione, the relative affinity
of cisplatin for PS was found to be low. Moreover, loading erythrocyte ghosts with physiological concentrations of
glutathione strongly reduced cisplatin-PS complexation. Thus, in intact (tumor) cells a complex is not detected, most likely,
because of the presence of higher affinity substrates. Though a transient complexation of cisplatin to PS cannot be excluded,
our data suggest that cisplatin-PS does not play a direct role in the cellular (cyto)toxicity of cisplatin. ß 1999 Elsevier
Science B.V. All rights reserved.
Keywords: Anti-cancer drug; Cancer; Cisplatin; Glutathione; Phosphatidylserine; Phospholipid
1. Introduction
Cisplatin, cis-diamminedichloroplatinum(II), is a
widely used anti-tumor drug, and very e¡ective in
the treatment of testicular, ovarian, bladder, head
and neck, esophageal, and small cell lung cancers
[1]. The major limitation of cisplatin in the clinic is
the development of cellular resistance. Cellular resist-
ance against cisplatin is multifactorial and may in-
volve an increase in thiols such as glutathione, en-
hanced DNA repair, enhanced tolerance to
platinum-DNA adducts, as well as drug accumula-
tion defects [2]. Besides that, cisplatin has a number
of serious side e¡ects, in particular nephrotoxicity
and peripheral neuropathy [3,4]. Cisplatin enters
the cell by a combination of passive di¡usion and
protein-mediated uptake [5], and then interacts with
a variety of intracellular biomolecules [6,7]. In par-
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ticular sulfur- and nitrogen-donor atoms have a high
a⁄nity for cisplatin. Interaction with nuclear DNA,
especially at the N7 position of guanine bases, ap-
pears to be responsible for the anti-tumor activity of
cisplatin [8^11]. Apart from DNA and RNA, cispla-
tin interacts with proteins and peptides. Hydrolysis
of cisplatin is the rate-limiting step in the reaction of
cisplatin with most biomolecules [6,12]. Hydrolysis
involves the replacement of the chloride atoms by
water, and results in mono- and diaquated cisplatin.
The formation of these highly reactive positively
charged species of cisplatin is enhanced at the low-
chloride concentrations found intracellularly.
Cisplatin was recently found to interact with neg-
atively charged phospholipids [13,14] forming a co-
ordination complex with phosphatidylserine (PS).
Complexation of cisplatin to PS involves loss of
both chloride atoms and coordination of platinum
to the amine and carboxylate groups of the serine
moiety [15]. PS is enriched at the plasma membrane,
virtually con¢ned to the inner, cytosolic, lea£et of the
membrane where it represents about 20% of the
phospholipids. PS plays an important role in cellular
processes such as signal transduction [16], cell prolif-
eration and apoptosis [17^19], the blood clotting cas-
cade [20], and the biogenesis of mitochondria [21],
and is necessary for the activity of a number of mem-
brane enzymes such as the (Na+K)-ATPase [22]
and protein kinase C [16]. Our initial study describ-
ing coordination of cisplatin to PS was performed in
vitro using pure lipid model membranes and isolated
erythrocyte membranes [15]. A similar interaction in
vivo would be expected to have important physiolog-
ical implications, and might be responsible for some
of the side e¡ects of cisplatin. Therefore, we have
now extended our study of cisplatin-PS interaction
to intact human erythrocytes and well-established
human tumor cell lines.
2. Materials and methods
2.1. Materials
Cisplatin, reduced and oxidized glutathione, 5P-
GMP, and L-methionine were obtained from Sigma
(St. Louis, MO, USA) and digitonin from BDH
(Poole, UK). Phospholipids were from Avanti Polar
Lipids (Birmingham, AL, USA). Cell culture media
and solutions were from Gibco (Glasgow, UK), and
culture plastics from Costar (Cambridge, MA, USA).
All other chemicals and solvents were of analytical
grade.
2.2. Cells
Cells were grown on plastic culture dishes in the
presence of 100 U/ml penicillin and 100 Wg/ml strep-
tomycin, HepG2 cells in MEM with 10% FCS [23],
IGROV-1 [24] in RPMI supplemented with 25 mM
HEPES and 10% FCS, Caco-2 (HTB-37, American
Type Culture Collection, Rockville, ML, USA) in
DMEM with 1% non-essential amino acids and
10% FCS [25], and MCF-7 in DMEM with 10%
FCS. All cell lines were routinely checked and found
to be free of mycoplasm infections. For experiments,
cells were grown on 6 cm dishes and used at 60^90%
con£uence.
2.3. Cisplatin stocks and incubation bu¡ers
Cisplatin was dissolved in the dark, in bu¡er or
tissue culture medium to a ¢nal concentration of 2^
8 mM. The solution was incubated for 1 h at 55‡C
(bu¡ers) or 37‡C (culture media) and intermittently
vortexed or brie£y sonicated (6 30 s) using a bath
sonicator until properly dissolved. Stock solutions of
cisplatin in chloride-free bu¡ers were incubated over-
night at 37‡C to ensure full equilibration of cisplatin.
Cisplatin stocks were prepared in the following bu¡-
ers and culture media: PIPES-sulfate bu¡er (10 mM
PIPES-NaOH, 100 mM Na2SO4, 1 mM EGTA, pH
7.4), phosphate bu¡er (5 mM phosphate, pH 8.0),
HBSS-HEPES bu¡er (Hanks’ balanced salt solution
with 10 mM HEPES-NaOH, pH 7.4), HEPES-ace-
tate bu¡er (20 mM HEPES-KOH, 110 mM KOAc,
2 mM MgOAc, pH 7.2 [26]), complete growth me-
dium (MEM-bicarbonate with 10% FCS), and
MEM-HEPES (MEM without bicarbonate, with
10 mM HEPES-NaOH, pH 7.4).
2.4. Interaction of cisplatin with erythrocyte
membranes
Isolated human erythrocytes without bu¡y coat
were obtained from the local blood bank in
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150 mM NaCl, 50 mM glucose, 30 mM mannitol,
and 1.2 mM adenine, and stored at 4‡C. Erythro-
cytes were used either within 1 week after blood
donation (‘fresh’), or in the second-to-third month
after blood donation (‘aged’). Before the actual ex-
periment, erythrocytes were washed 3 times in phos-
phate-bu¡ered saline (PBS, 150 mM NaCl, 10 mM
phosphate, pH 7.4) and up to 3 times in the incuba-
tion bu¡er, using centrifugation and resuspension (10
min, 2300Ugmax), and cell number was determined
using a Fuchs-Rosenthal counting chamber. During
a typical incubation with cisplatin, the pelleted eryth-
rocytes (‘packed cells’) were diluted 10 times and
aliquots of 1 ml were analyzed. To determine the
in£uence of membrane permeability and of cytosol
on cisplatin-PS complexation, packed erythrocytes in
PIPES-sulfate bu¡er were freeze-thawn 10 times, us-
ing dry ice in ethanol and a 37‡C waterbath, and the
released cytosol was removed by repeated centrifuga-
tion and resuspension in PIPES-sulfate bu¡er
(10 min, 30 000Ugmax at 4‡C). Identical amounts of
control and pretreated erythrocytes were diluted
3 times in cisplatin-containing PIPES-sulfate bu¡er
(¢nal concentration of cisplatin of 5 mM) and incu-
bated at 37‡C. Cisplatin-PS complexation was also
studied in erythrocyte membranes isolated after hy-
potonic lysis: unsealed (‘open’) ghost, pink sealed
ghost, and white sealed ghost prepared according
to Steck and Kant [27], as well as pink resealed ghost
prepared according to Wood and Passow [28] (also
see [29]). The ghosts were prepared from fresh eryth-
rocytes and used the same day; resealing bu¡ers did
not contain Ca2. Open ghost preparations were
freeze-thawn 3 times to maximize membrane perme-
ability and to minimize resealing during incubation
with cisplatin. Before use, ghost preparations were
washed 3 times in the incubation bu¡er by centrifu-
gation and resuspension (10 min, 30 000Ugmax at
4‡C). The degree of membrane impermeability of
ghosts sealed in low ionic strength bu¡er was deter-
mined by assaying the accessibility of intracellular
glyceraldehyde-3-phosphate dehydrogenase to exter-
nally added substrate [27]. Alternatively, at the end
of an incubation with cisplatin the accessibility of
cisplatin-PS complex to externally added glutathione
was determined. To this end, aliquots were incubated
with 100 mM reduced glutathione at 37‡C and the
fraction of cisplatin-PS complex resisting glutathione
treatment was followed in time. To determine the
e¡ects of intracellular glutathione on cisplatin-PS
complexation, pink ghosts [28] were loaded with 10
mM reduced glutathione in PIPES-sulfate bu¡er. Ex-
tracellular glutathione was removed by repeated cen-
trifugation and resuspension in PIPES-sulfate bu¡er.
As a control, ghosts loaded with glutathione were
freeze-thawn 3 times to release most of the intracel-
lular glutathione before incubating with cisplatin.
2.5. Interaction of cisplatin with tumor cells
HepG2, IGROV-1, Caco-2, and MCF-7 cell
monolayers on 6 cm culture dishes were washed
3 times with the appropriate incubation medium,
and incubated for 1^18 h with 1^5 mM cisplatin in
the same medium at 37‡C in a waterbath or, if a
bicarbonate-containing medium was used, in a CO2
incubator. The following incubation media were
used: HBSS-HEPES, DMEM with 10% FCS (com-
plete growth medium), DMEM-HEPES, and acetate-
HEPES; less than 10% of the cells detached during
an overnight incubation with cisplatin. After incuba-
tion with cisplatin, the cells were rinsed twice with
PBS or HBSS-HEPES, scraped, and the lipids ex-
tracted and analyzed by two-dimensional TLC using
iodine staining (see later). To improve the sensitivity
of lipid detection, cells were metabolically labeled
with L-[3-3H]- or L-[3-14C]serine (speci¢c activities
of 962 GBq/mmol and 2.15 GBq/mmol, respectively;
Amersham International, Buckinghamshire, UK) for
20^24 h at 37‡C in MEM-bicarbonate, 10% FCS,
using 2 ml 75 KBq/ml (3H) or 20 KBq/ml (14C) per
dish. Dishes were rinsed 3 times before incubation
with cisplatin. Radiolabeled lipids were detected by
autoradiography or phosphor-imaging (see later).
For experiments on semi-intact cells, cell monolayers
were rinsed with acetate-HEPES bu¡er and cells per-
meabilized with digitonin, 100 Wg/ml (added from a
stock of 20 mg/ml DMSO) for 10 min at 20‡C. Al-
ternatively, cells were permeabilized by freeze-thaw-
ing, £oating the culture dish on liquid nitrogen and
thawing at 37‡C. In both cases, more than 95% of
the cells stained blue in a trypan blue exclusion assay
(0.2% trypan blue, 2 min at 20‡C) indicating that
more than 95% of the cells had been permeabilized.
Dishes were rinsed 3 times at 37‡C before incubation
with cisplatin.
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2.6. Interaction of cisplatin with phospholipid
dispersions
In competition experiments, cisplatin-PS complex-
ation was determined in DOPS/DOPC (1:1, mol/
mol) liposomes in the presence of increasing concen-
trations of alternative substrates for cisplatin. Multi-
lamellar vesicles (lipid concentration 2 mM) were
prepared by hydration of a dry lipid ¢lm in PIPES-
sulfate bu¡er containing either 1 mM or 5 mM cis-
platin, and 0, 1, 5, or 10 mM of reduced or oxidized
glutathione, L-methionine, or 5P-GMP. The lipo-
somes were freeze-thawn 10 times and the degree of
cisplatin-PS complexation was determined after an
overnight incubation at 37‡C.
2.7. Lipid analysis
Before lipid extraction, erythrocytes were lysed in
distilled water to release the hemoglobin, and the
membranes isolated by centrifugation (10 min,
30 000Ugmax at 4‡C) and resuspended in saline. Lip-
ids were extracted according to Bligh and Dyer [30].
All aqueous solutions were acidi¢ed to 10 mM acetic
acid, KCl was added during phase separation (0.44%
w/v). Lipids were separated by two-dimensional TLC
on HPTLC plates (Si60, Merck, Darmstadt, Ger-
many) using in the ¢rst dimension (I in Fig. 1),
chloroform/methanol/ammonia, 25%/water (90:54:
5.5:5.5, v/v) and in the second dimension (II in
Fig. 1), chloroform/methanol/acetic acid/water (90:
40:12:2, v/v). Lipids were detected by sulfuric acid
or iodine staining, identi¢ed by comigration with
known standards, and phospholipids quanti¢ed by
6
Fig. 1. Interaction of cisplatin with PS in the human erythro-
cyte membrane analyzed by two-dimensional TLC and staining
with sulfuric acid. Fresh erythrocytes were incubated with cis-
platin (5 mM in PIPES-sulfate bu¡er, pH 7.4, overnight at
37‡C) without pretreatment (A), after being freeze-thawn to in-
duce membrane defects and release cytosol (B), or after being
freeze-thawn and depleted of cytosol by repeated centrifugation
and resuspension (C). Cisplatin-PS complex (arrow) was only
barely detectable in intact erythrocytes (compare A with B,C).
The amount of cisplatin-PS complexation was determined by
phosphate determination after two-dimensional TLC (see Table
1). I and II, ¢rst and second dimension of TLC; O, origin;
SM, sphingomyelin; PC, phosphatidylcholine; PE, phosphatid-
ylethanolamine; PS, phosphatidylserine; Hb, hemoglobin.
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phosphate determination [31]. Cisplatin-PS has a
lower Rf value than PS [15], and stains in iodine
vapor brownish instead of yellow. When liposomes
were prepared from a total lipid extract of human
erythrocytes or tumor cell lines and treated with cis-
platin, the cisplatin-PS complex exactly colocalized
with cisplatin-DOPS after two-dimensional TLC
(not shown). Tritiated lipid was detected by autora-
diography after dipping the TLC plates in 0.4% PPO
dissolved in 2-methylnaphthalene supplemented with
10% xylene; pre£ashed Kodak X-Omat S ¢lms were
exposed for 2^4 days at 380‡C. 14C-Labeled lipids
were detected by phosphor image analysis and quan-
titated using ImageQuant software (Molecular Dy-
namics, Sunnyvale, CA, USA).
2.8. Platinum determination
After incubation with cisplatin, erythrocytes and
erythrocyte ghost were washed 6 times in PIPES-
sulfate bu¡er using centrifugation (1 min,
1000Ugmax) and resuspension. The intracellular dis-
tribution of cisplatin in erythrocytes was determined
by lysing the erythrocytes in 5 mM phosphate bu¡er
(pH 8.0), and pelleting the membranes (10 min,
30 000Ugmax at 4‡C). Lysis and centrifugation were
repeated, and the Pt content of membrane pellet and
the pooled supernatant was determined. Prior to Pt
determination, tumor cell monolayers on plastic were
washed 6 times in PBS and scraped using a rubber
policeman. Samples were digested before Pt analysis:
aliquots were transferred to screw-capped Eppendorf
cups and dried in a speedvac centrifuge (Swart,
Hicksville, NY), after which 200 Wl 65% HNO3 was
added and the tightly sealed cups incubated for 2 h
at 75‡C. The Pt content was determined after dilu-
tion in water by £ameless atomic absorption spec-
trometry using a SpectrAA-400 Zeeman spectrometer
equipped with an autosampler (Varian, Palo Alto,
CA, USA). The method of van Warmerdam et al.
[32] was used, with K2PtCl6 (Sigma) as a standard.
In short, a total volume of 35 Wl was introduced into
the graphite tube consisting of 5 Wl of modi¢er sol-
ution (0.5% Triton X-100 in water, v/v) and 30 Wl
sample or Pt standard containing 1^8 ng Pt. After
drying at 85^120‡C for 1 min, and charring at
1400‡C for 8 s, Pt absorbance was measured at
2700‡C for 3.3 s.
Table 1
Interaction of cisplatin with PS in the human erythrocyte membranea
Sample Incubation bu¡er Cisplatin (mM) Cisplatin-PS (% of total PS)
Ery, intact PIPES-sulfate 2 1.1 þ 1.7b
Ery, intact PIPES-sulfate 5 4.7 þ 2.3b
Ery, freeze-thawn PIPES-sulfate 5 10.7 þ 0.4b
Ery, freeze-thawn, washed PIPES-sulfate 5 52.3 þ 0.9b
Open ghost PIPES-sulfate 2 24.8 þ 2.2c
Sealed pink ghostd PIPES-sulfate 2 23.6 þ 7.9b
Sealed white ghost PIPES-sulfate 2 21.3 þ 0.7c
Open ghost PIPES-sulfate 5 46.6
Sealed white ghost PIPES-sulfate 5 54.9 þ 0.6c
Open ghost 5 mM phosphate 5 82.4
Sealed pink ghoste 5 mM phosphate 5 75.8
aHuman erythrocyte and erythrocyte membrane preparations were incubated overnight at 37‡C with cisplatin, and the amount of cis-
platin-PS complexation was determined after two-dimensional TLC as described in Section 2 (baverage þ S.D. with n = 3^6; caverage
and range with n = 2). Erythrocytes were used within 1 week after blood donation (‘intact’), freeze-thawn to induce membrane defects
and release cytosol, or freeze-thawn and cytosol washed away by repeated centrifugation and resuspension. Open erythrocyte ghost
and sealed white ghost were prepared according to Steck and Kant [27], and sealed pink ghost according to dWood and Passow [28]
or eSteck and Kant [27]. Ghosts were resuspended and incubated with cisplatin in PIPES-sulfate bu¡er or in a low-ionic strength
phosphate bu¡er. The more e⁄cient cisplatin-PS complexation in 5 mM phosphate bu¡er as compared to that in PIPES-sulfate bu¡er,
is due to the lower ionic strength of the former bu¡er (see [6]). Over 85% of the ghosts sealed in phosphate bu¡er were intact at the
start of the incubation with cisplatin, while in general about 60% of the pink ghost prepared according to Wood and Passow [28] are
properly sealed [44]. For details see text.
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3. Results and discussion
3.1. Interaction of cisplatin with intact human
erythrocytes
In a previous paper we described that a complex
between cisplatin and phosphatidylserine forms in
PS-containing model membranes as well as in bio-
membranes [15]. However, the experiments on bio-
membranes were performed using open erythrocyte
ghost, leaky erythrocyte membranes which almost
completely lack any cytosolic contents. Therefore,
we extended our original study and compared the
interaction of cisplatin with PS in erythrocyte mem-
brane preparations with that in intact erythrocytes.
Because it is the positively charged aquated species of
cisplatin which reacts with PS [15], experiments were
performed in a bu¡er lacking chloride, i.e. with
aquated cisplatin, which is e⁄ciently taken up by
intact (tumor) cells [33,34]. Fig. 1 and Table 1
show the results obtained upon incubation of human
erythrocytes and various erythrocyte membrane
preparations with 2 or 5 mM cisplatin, overnight at
37‡C in a neutral pH bu¡er lacking chloride. A com-
plex between cisplatin and PS was virtually absent if
freshly isolated human erythrocytes were used in the
experiment, in many cases the amount of complex
formed was even too low to be detected by iodine
staining indicating that less than 1% of cellular PS
had reacted with cisplatin (intact erythrocytes incu-
bated with 2 mM cisplatin, see Table 1). In contrast,
if outdated erythrocyte concentrate was obtained
from the blood bank and used as starting material,
a signi¢cant part of cellular PS, about 10%, reacted
with cisplatin (data not shown). Upon prolonged
storage, erythrocytes release hemoglobin indicative
of a deterioration of the barrier properties of the
plasma membrane. Therefore, the fact that cispla-
tin-PS complexation was facilitated in aged erythro-
cyte preparations might be related to an increased
permeability of the erythrocyte membrane. To exam-
ine this possibility, membrane damage was induced
in freshly isolated erythrocytes by freeze-thawing. In-
deed, when freshly isolated packed erythrocytes were
freeze-thawn and subsequently incubated with cispla-
tin, again about 10% of cellular PS was converted
into the cisplatin-PS complex (Fig. 1B, Table 1). Pro-
longed storage and freeze-thawing not only result in
an increase in membrane permeability but also in
release of cytosolic components. To answer the ques-
tion which of these events was responsible for the
increase in cisplatin-PS complexation, packed eryth-
rocytes were freeze-thawn and the released cytosol
was removed. Over 50% of cellular PS complexed
to cisplatin (Fig. 1C, Table 1), strongly suggesting
that in the intact erythrocyte, cytosol competes
with PS for cisplatin.
Almost pure erythrocyte membranes can be ob-
tained after hypotonic lysis using well-established
methods [27,28], the so-called open erythrocyte
ghosts contain large holes which reseal in a suitable
bu¡er; as long as Ca2 is absent from the resealing
bu¡er, the asymmetric phospholipid distribution is
not a¡ected by these procedures [35,36]. The intact-
ness of sealed ghost preparations can be determined
by assaying the latency of a membrane-bound intra-
cellular enzyme, glyceraldehyde-3-phosphate dehy-
drogenase ([27] and references therein). This enzyme
latency assay, which can only be applied at low ionic
strength, indicated that over 85% of the pink ghost
sealed in a low ionic strength bu¡er was intact at the
start of the cisplatin incubation. Attempts to monitor
the intactness of sealed ghost during incubation with
cisplatin failed; enzyme latency or leakage of residual
hemoglobin could not be reliably measured because
cisplatin strongly reduced the activity of glyceralde-
hyde-3-phosphate dehydrogenase and shifted the ab-
sorption spectrum of hemoglobin (data not shown).
6
Fig. 2. Interaction of cisplatin with PS in human tumor cell lines. IGROV-1 cell monolayers metabolically labeled overnight with L-3-
[3-3H]serine (A^D) or L-3-[3-14C]serine (E,F) were incubated at 37‡C with 5 mM cisplatin in HBSS-HEPES (A^D) or acetate-HEPES
(E,F). In A^D, the lipid composition was followed in time (0, 1, 3, and 18 h incubation with cisplatin, respectively). In F, cells were
permeabilized by freeze-thawing, prior to incubation with cisplatin for 18 h (E, control, intact cells incubated with cisplatin for 18 h).
Lipids were separated by two-dimensional TLC and detected by autoradiography (A^D) or phosphor-imaging (E,F) as described in
Section 2. An additional spot, the cisplatin-PS complex (arrow in F), was only detected in permeabilized cells ; this spot was not ob-
served in control (permeabilized) cells incubated in the absence of cisplatin (not shown). Identical results were obtained in HepG2,
Caco-2, and MCF-7 cells (not shown), for details see text. GL, glycolipid (other abbreviations are explained in the legend of Fig. 1).
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However, it is reasonable to assume that a signi¢cant
fraction of the sealed ghosts remained intact. Thus,
the fact that in open and sealed ghosts cisplatin re-
acted with PS to an almost identical extent (Table 1)
indicates that membrane passage of cisplatin is not a
limiting factor, and strongly suggests that the ab-
sence of cisplatin-PS complex in intact erythrocytes
is not due to a failure of cisplatin to pass the plasma
membrane, but to the presence of cytosol. Cytosolic
components apparently prevent a stable association
between intracellular cisplatin and the PS present in
the inner lea£et of the erythrocyte membrane. This
conclusion is supported by measurements of cisplatin
uptake and binding. After an overnight incubation
with 2 mM cisplatin in PIPES-sulfate bu¡er, intact
erythrocytes, open, and resealed pink ghost [28] con-
tained 11.8, 0.8, and 1.3 nmol cisplatin/nmol PS, re-
spectively (data not shown). Thus, intact erythro-
cytes contained 9^15 times more cisplatin than
open or sealed ghost, yet were virtually devoid of
cisplatin-PS complex. Moreover, freeze-thawing of
these erythrocytes released 79 þ 3% (n = 2) of the
cell-associated cisplatin indicating that in intact
erythrocytes cisplatin is predominantly present in
the cytosol (data not shown; in agreement with [37]).
3.2. Interaction of cisplatin with human tumor cell
lines
Next we examined the interaction of cisplatin with
PS in a number of human tumor cell lines, hepatoma
HepG2, colon carcinoma Caco-2, breast MCF-7, and
ovarian IGROV-1. After two-dimensional TLC and
iodine staining, cisplatin-PS complexation was not
detected in any of the tumor cell lines (results not
shown). To check whether the inability to detect cis-
platin-PS was due to the insensitivity of the detection
method, cells were metabolically labeled with L-
[3-3H]- or L-[3-14C]serine overnight and the resulting
radiolabeled lipids were detected after two-dimen-
sional TLC by autoradiography and phosphor-imag-
ing respectively. Phosphatidylserine was e⁄ciently
radiolabeled in all four cell lines; Fig. 2A shows a
typical result for IGROV-1 cells labeled overnight
with [3-3H]serine. After radiolabeling, the cells were
incubated with cisplatin and the cisplatin-PS com-
plexation was followed in time at 37‡C. Fig. 2B^D
show the results obtained for IGROV-1 cells incu-
bated for up to 18 h with 5 mM cisplatin in HBSS-
HEPES: cisplatin-PS complexation was not detected.
Identical results were obtained using concentrations
of cisplatin of 0.1^5 mM, and incubation media such
as DMEM with 10% FCS (complete growth me-
dium), DMEM-HEPES, or an acetate-HEPES bu¡er
lacking chloride [26]. Cisplatin-PS complexation was
not detected in any of the cell lines as long as cells
remained intact; however, cisplatin-PS was detected
in cells permeabilized by freeze-thawing or digitonin
treatment. A typical example is shown in Fig. 2F,
IGROV-1 cells labeled with [14C]serine, permeabi-
lized by freeze-thawing, and incubated overnight
with 5 mM cisplatin in acetate-HEPES bu¡er (cf.
Fig. 2E, intact cells treated with cisplatin): 25.9%
of PS is complexed to cisplatin. Data obtained on
the cellular uptake of cisplatin in intact IGROV-1
cells indicate that during an overnight incubation
with 5 mM cisplatin 33.5 þ 0.1 nmol cisplatin is taken
up per nmol PS (n = 2; data not shown). Thus, in
analogy to the results obtained on cisplatin-PS com-
plexation in the erythrocyte membrane, the failure to
detect cisplatin-PS complex in intact cells is not due
to ine⁄cient uptake of cisplatin but most likely to
competing substrates being present in the cytosol.
3.3. Interaction of cisplatin with PS and alternative
cellular substrates
The cytosol contains a number of nucleophilic li-
gands which are potentially competing with PS for
cisplatin. The nucleophilicities of sulfur atoms are
particularly high, and eukaryotic cells contain rela-
tively high concentrations of thiols, especially gluta-
thione. Reduced glutathione, present in the cytosol at
concentrations between 0.5 and 10 mM, exists in
equilibrium with an about 500-fold lower concentra-
tion of oxidized glutathione [38]. Other potential sub-
strates for cisplatin are methionine-containing pro-
teins and peptides, and especially the guanine bases
in RNA and DNA [6,7]. In order to determine the
relative a⁄nity of cisplatin for PS, PS-containing lip-
osomes were incubated with cisplatin in the presence
of increasing concentrations of the alternative cellu-
lar substrates, reduced and oxidized glutathione, L-
methionine, and 5P-GMP. The extent to which cis-
platin-PS complexation still occurred was determined
after an overnight incubation at 37‡C (Fig. 3). In
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most cases, an equimolar concentration of the alter-
native substrate relative to PS (1 mM) already re-
duced cisplatin-PS complexation by a factor 3^4;
only if oxidized glutathione was used, a molar excess
was required to inhibit cisplatin-PS complexation.
Simple calculations show that reduced glutathione
may very well prevent cisplatin-PS complexation.
Human erythrocytes have an average volume of 90
Wm3 [39], and packed human erythrocytes contain
per ml, about 5.109 cells, 2100 nmol glutathione
[40], and 510 nmol PS (determined by lipid analysis).
Thus, the cytosolic glutathione concentration is close
to 5 mM and the molar ratio of glutathione to PS is
4. In the case of nucleated cells, accurate morpho-
metric data are only available for a limited number
of cell lines, such as dog kidney MDCK-I cells [41].
These cells have a volume of 1500 Wm3 and contain
2.5 nmol PS per 106 cells [42], while the glutathione
concentration in (human) kidney is about 3 mM (see
[43]); from these data a glutathione-to-PS molar ra-
tio of 1.8 can be calculated. These calculations show
that in most cells reduced glutathione will be present
in 2^4-fold molar excess relative to PS, which, based
on the results of the competition experiments (Fig.
3), would be expected to inhibit cisplatin-PS com-
plexation almost completely.
To obtain more direct evidence for the role of
glutathione in preventing cisplatin-PS complexation,
erythrocyte ghosts were sealed in the presence and
absence of glutathione, washed, and incubated with
cisplatin (Table 2). When ghosts were sealed in bu¡er
and incubated overnight with 2 mM cisplatin, 31% of
cellular PS was converted into cisplatin-PS. Com-
Fig. 3. Cisplatin-PS complexation in the presence of alternative
substrates for cisplatin. Multilamellar DOPS/DOPC (1:1, mol/
mol, 2 mM lipid) vesicles in PIPES-sulfate bu¡er were incu-
bated overnight at 37‡C with 1 mM cisplatin and up to 10 mM
of an alternative substrate (E, reduced glutathione; 7, oxidized
glutathione; a, L-methionine; O, 5P-GMP), and the degree of
cisplatin-PS complexation was determined after two-dimensional
TLC (see Section 2). An equimolar concentration of the alter-
native substrate relative to PS strongly reduced cisplatin-PS
complexation; the same result was obtained using 5 mM in-
stead of 1 mM cisplatin (not shown).
Table 2
In£uence of glutathione on the interaction of cisplatin with PS in human erythrocyte membranesa
Pink ghost loaded with Cisplatin (mM) Cisplatin-PS (% of total PS)
Bu¡er 2 31.0
Glutathione 2 17.3
Bu¡er (freeze-thawn) 2 32.9
Glutathione (freeze-thawn) 2 38.6
Bu¡erb 2
Post-incubation with 100 mM glutathione at 37‡C (min)
0 31.0
30 12.7
120 15.8
aGhosts were incubated overnight at 37‡C with cisplatin in PIPES-sulfate bu¡er and the amount of cisplatin-PS complex was deter-
mined. Pink ghosts [28] were sealed in PIPES-sulfate bu¡er, or in PIPES-sulfate bu¡er containing 10 mM reduced glutathione; extra-
cellular glutathione was removed by repeated centrifugation and resuspension. Ghosts were freeze-thawn to induce membrane permea-
bilization and, in the case of ghost loaded with glutathione, release intracellular glutathione.
bThe intactness of the ghosts (loaded with bu¡er) after an overnight incubation with 2 mM cisplatin was determined by assaying for
the accessibility of the cisplatin-PS complex to externally added glutathione (100 mM, 37‡C). The results of a typical experiment are
shown. For details, see text.
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plexation was strongly reduced if ghosts were loaded
with 10 mM glutathione, only 17% complex was
formed. To determine whether cisplatin-PS complex-
ation was inhibited by intracellular glutathione or by
glutathione possibly released from the ghosts, part of
the samples were freeze-thawn prior to incubation
with cisplatin. Freeze-thawing resulted in a complete
loss of the inhibitory e¡ect of glutathione on cispla-
tin-PS complexation, indicating that in our experi-
mental setup released glutathione was diluted to
such an extent that it did not interfere with cispla-
tin-PS complexation. The small increase in complex-
ation observed in freeze-thawn versus intact ghosts is
likely due to an increase in membrane permeability
induced by freeze-thawing. Together these data
clearly show that glutathione, at physiological con-
centrations, strongly inhibits cisplatin-PS complexa-
tion. Based on the competition experiments (Fig. 3),
10 mM glutathione would be expected to reduce cis-
platin-PS complexation by at least 90%. The reason
why loading ghosts with 10 mM glutathione reduced
complexation by only 43%, is the rather low e⁄-
ciency of ghost resealing, and the fact that gluta-
thione will only inhibit complexation in sealed
ghosts. In general about 60% of the ghosts reseal
properly during ghost preparation [44], and part of
these sealed ghosts may become leaky during over-
night incubation with cisplatin. Because the assays
normally used to monitor membrane permeability
of erythrocyte ghost failed in the presence of cisplatin
(see Section 3.1), a novel method was developed to
determine the fraction of intact ghosts at the end of
the cisplatin incubation. The method makes use of a
post-incubation with a high concentration of gluta-
thione and is based on the fact that glutathione is
capable of reversing cisplatin-PS complexation but
does not pass intact membranes. Thus, if glutathione
is added to ghosts treated with cisplatin, only the
cisplatin-PS complex present in leaky ghosts will be
lost; an incubation with 100 mM glutathione for 1 h
at 37‡C is su⁄cient to remove all accessible cisplatin-
PS [15]. When sealed ghosts were treated with 2 mM
cisplatin overnight, and subsequently incubated with
100 mM glutathione, cisplatin-PS complexation was
reduced by 50^60%, indicating that 40^50% of cis-
platin-PS was protected inside properly sealed
ghosts. Thus, only 40^50% of cisplatin-PS complex-
ation can be prevented by loading ghosts with gluta-
thione, and the observed reduction in complexation
by 43% shows that 10 mM glutathione is capable of
nearly completely preventing cisplatin-PS complexa-
tion in intact erythrocyte ghosts.
3.4. Role of cisplatin-PS complexation in cisplatin-
induced (cyto)toxicity
Cisplatin is generally used in the clinic at a dose of
100 mg/m2 given intravenously, and the peak concen-
tration in the blood measured directly after i.v. in-
jection is about 30^35 WM [45]. Although cisplatin
e⁄ciently forms a stable coordination complex with
phosphatidylserine in vitro, both in pure lipid model
systems and puri¢ed biomembrane systems, we were
unable to detect the cisplatin-PS complex in intact
erythrocytes or tumor cells, even at cisplatin concen-
trations much higher than the clinically achievable
concentration. Therefore we consider it unlikely
that cisplatin-PS complexation plays a direct role in
the cellular (cyto)toxicity of cisplatin.
In view of the molar excess of glutathione relative
to PS, and the e⁄ciency with which glutathione re-
duces cisplatin-PS complexation, glutathione is prob-
ably one of the key factors responsible for the ab-
sence of cisplatin-PS complex in intact cells treated
with cisplatin. Glutathione is both capable of pre-
venting cisplatin-PS complexation by competing
with PS for cisplatin binding, as well as capable of
reversing cisplatin-PS complexation [15]. Thus, either
cisplatin-PS complexation does not occur because
cisplatin reacts preferentially with glutathione, or cis-
platin-PS complexation does occur but is followed by
a rapid transfer of cisplatin to other cellular sub-
strates, such as glutathione. The latter possibility is
not excluded because while entering the cell, cisplatin
passes the PS present in the cytosolic lea£et of the
plasma membrane before contacting alternative sub-
strates in the cytosol.
An intriguing question remains as to how cisplatin
reaches its ultimate target, nuclear DNA, despite the
presence of scavengers for cisplatin, such as gluta-
thione, being present in the cytosol. Although for
some of the cytosolic nucleophiles binding to cispla-
tin appears to be reversible allowing transfer of the
platinum compound to DNA, in vitro experiments
also indicated that such a transfer is extremely un-
likely in the case of glutathione [46^48].
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The positively charged aquated species of cisplatin
are most likely responsible for DNA adduct forma-
tion and the induction of apoptosis. The fact that the
cytosolic face of the plasma membrane and many
intracellular membranes contain high concentrations
of negatively charged phospholipids, in particular
phosphatidylserine, may facilitate aquation and
thus activate cisplatin. Our future research will focus
on the potential role of membrane lipids, in the cel-
lular uptake of cisplatin, and in the intracellular ac-
tivation of this highly potent anti-tumor drug.
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